References
- WHO. Global tuberculosis report 2019. Geneva World Health Organ. 2019; Licence: CC BY-NC-SA 3.0 IGO.
- Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med. 2015;3:963–972.
- Shah NS, Auld SC, Brust JCM, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med. 2017;376(3):243–253. .
- Hopewell S, Clarke MJ, Stewart L, et al. Time to publication for results of clinical trials. Cochrane methodology review group, editor. Cochrane Database Syst Rev. 2007; Internet]. DOI:10.1002/14651858.MR000011.pub2.
- Nunn AJ, Phillips P, Mitchison D. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis. 2010;14:241–242.
- WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva world health organ. 2019; Licence: CC BY-NC-SA 3.0 IGO.
- WHO. Guidelines for the programmatic management of drug-resistant tuberculosis-2008. WHO Geneva Switz 2008; WHO/HTM/TB/2008.402.
- Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397–2405.
- Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151–2160.
- von Groote-bidlingmaier F, Patientia R, Sanchez E, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7:249–259.
- Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med. 2019;380:1201–1213.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. .
- WHO. Rapid communication: key changes to treatment of drug-resistant tuberculosis. Geneva World Health Organ. 2019.
- Schunemann HJ. All evidence is real world evidence. Blog. 2019. Available from: https://blogs.bmj.com/bmj/2019/03/29/holger-j-schunemann-all-evidence-is-real-world-evidence/
- Collins R, Bowman L, Landray M, et al. The magic of randomization versus the myth of real-world evidence. N Engl J Med. 2020;382(7):674–678.
- Lienhardt C, Vernon AA, Cavaleri M, et al. Development of new TB regimens: harmonizing trial design, product registration requirements, and public health guidance. PLOS Med. 2019;16(9):e1002915. .
- Phillips PPJ, Mitnick CD, Neaton JD, et al. Keeping phase III tuberculosis trials relevant: adapting to a rapidly changing landscape. PLOS Med. 2019;16:e1002767.
- Schumi J, Wittes JT. Through the looking glass: understanding non-inferiority. Trials. 2011;12:106.
- Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British medical research council tuberculosis units, 1946–1986, with relevant subsequent publications. Internaional J Tuberc Lung Dis. 1999;3:S231–S279.
- McKenna L, Furin J. Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? Lancet Respir. Med. 2019;7:999–1000.
- Byar D. Design considerations for AIDS trials. J Acquir Immune Defic Syndr. 1990;3:S16–19.
- Global TB Community Advisory Board. Research, regulatory, and access considerations regarding pretomanid. Cited 2020 Apr 10. http://www.tbonline.info/media/uploads/documents/tb_cab_pretomanid_nda_consideration
- FDA. Limited Population Pathway for antibacterial and antifungal drugs – the LPAD Pathway. Cited April 10, 2020. Available fromhttps://www.fda.gov/drugs/development-resources/limited-population-pathway-antibacterial-and-antifungal-drugs-lpad-pathway
- FDA. Limited population pathway for antibacterial and antifungal drugs; draft guidance for industry. comments. Cited 2020 Apr 10. Available from https://www.regulations.gov/docketBrowser?rpp=25&so=DESC‚commentDueDate£0&dct=PS&D=FDA-2018-D-2032
- Mitnick CD, Castro KG, Harrington M, et al. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 2007;4:e292.